| Protein Name: | Alpha-mannosidase 2 (Q16706) |
|---|---|
| Gene Name: | MAN2A1 |
| Description: | Alpha-mannosidase 2 (EC 3 2 1 114) (Alpha-mannosidase II) (Mannosyl- oliGOsaccharide 1,3-1,6-alpha-mannosidase) (MAN II) (GOlgi alpha- mannosidase II) (Mannosidase alpha class 2A member 1) |
| PDB ID: | |
| Protein Family: | |
| Protein Category: | Enzyme |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| swainsonine | Edema | Swainsonine@ administered by 5-day continuous infusion inhibited L-phytohemagglutinin-reactive N-linked oliGOsaccharide expression on peripheral blood lymphocytes by Inhibition of GOlgi alpha-mannosidase II that occurred in a dose-dependent manner@leads to Significant toxicities of edema [ ADR Type 1 ] | Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies |
| swainsonine | Toxicities Of Elevated Serum Aspartate Aminotransferase (Ast) | Swainsonine@ administered by 5-day continuous infusion inhibited L-phytohemagglutinin-reactive N-linked oligosaccharide expression on peripheral blood lymphocytes by Inhibition of Golgi alpha-mannosidase II that occurred in a dose-dependent manner@leads to Significant toxicities of elevated serum aspartate aminotransferase (AST). [ ADR Type 1 ] | Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies |
This panel provides information on drug category
| Toxicity | Source |
|---|